ALS Society of Alberta
Agrium Employee Ice Bucket Challenge
To support in the fight against a deadly disease, Agrium leaders are exploring the healing properties of some icy waters. On September 10, Agrium is taking on the Ice Bucket Challenge to raise funds and awareness for Amyotrophic Lateral Sclerosis (ALS).
To learn more about this event, or to donate please visit
The 2015 #ALSIceBucketChallenge
Funds raised support client support services in the province and national ALS research
Click to view the 2015 #ALSIceBucketChallenge Impact Report
Judy Van Dresar with family and friends, at the 2015 Grande Prairie WALK for ALS
"The ALS Society has gone above and beyond to support myself and my family with the necessary equipment and resources such as the equipment loan program and research forums to help me live a more manageable life. The Ice Bucket Challenge not only increases the programs and resources available but puts much needed funding toward research in order to find a treatment, if not a cure for this horrific disease," - Judy Van Dresar, ALS Alberta Client
Click to watch the Learning About ALS Alberta Primetime Special with Kyle Ruppe
Click to watch Dr. Korngut's report on the impact of the #ALSIceBucketChallenge in Alberta
Click here to download the Ice Bucket Challenge pledge form
WALK for ALS
There is ONE more WALK for ALS happening in Alberta this year!
Lethbridge (Sept. 13, 2015)
Henderson Lake Horseshoe Pit Group Picnic Area
Registration: 10 a.m.
WALK begins: 11 a.m.
Click here for more information or to register
2015 Postdoctoral Fellowship Recipients Announced
It is with great pleasure that ALS Canada announces the two recipients of 2015 postdoctoral fellowships awarded by the ALS Canada Research Program. As a result of the continued pursuance of a better understanding of the disease and new treatments to achieve our vision, it is imperative that promising young investigators are nurtured into a career focused on ALS research. Early postdoctoral years are when critical decisions are made in determining the direction of an individual's research and academic career. Supporting the highest calibre applicants at this stage provides the best possible chance for maintaining Canadian ALS research excellence in the future.
This year, we are fortunate to provide two fellowships at $55,000 per year for three years. These funds provide the salary for these talented individuals and ultimately assist the hosting lab and supervisor to better flourish in their contribution to the field of ALS research. Postdocs are the key implementers of the lab's vision and not only contribute to the direction of their work, but also execute the work to achieve results. The fellowship program is a fantastic investment and an important part of the ALS Canada Research Program that has previously nurtured individuals who are now global contributors to the field of ALS research as independent principal investigators.
2015 Doctoral Research Award Recipients Announced
It is with great pleasure that ALS Alberta announces the 2015 recipients of the Doctoral Research Awards, awarded by the ALS Canada National Research Program. As a result of continued pursuance of a better understanding of the disease and new treatments, it is imperative that promising young investigators are nurtured into a career focused on ALS research. Attracting the brightest young minds to ALS research will contribute to a succession plan for the Canadian ALS research community and will nurture the potential for younger perspectives to bring new ideas to the field.
The Doctoral Research Awards provide $25,000 per year over three years for salary to pursue a PhD in a Canadian laboratory. This funding also assists the hosting laboratory by offsetting funds that will help them to achieve their goals. As a result, it is a wise investment that will hopefully launch the career of a future leader in the field and further secure our ability to achieve the vision of making ALS a treatable, not terminal disease.
The Compassionate Care Benefit Gets Extended
We received good news today from the Government of Canada Budget 2015 announcement. The Compassionate Care Benefit has been officially extended from six to 26 weeks. This is a really important step forward to support caregivers who are caring for a loved one at home. We thank the federal government for their commitment to the extension of the CCB.
ALS ALBERTA SUPPORTS THE GOVERNMENT OF CANADA’S DECISION TO EXTEND THE COMPASSIONATE CARE BENEFIT TO 26 WEEKS
The ALS Society of Alberta is delighted to announce a wonderful new partnership! Mikael Backlund of the Calgary Flames has chosen the ALS Society of Alberta as one of his charities of choice!
Ice Bucket Challenge Funds New Clinical Trial
We are proud to announce funding for a new clinical trial from your donations through the ALS Ice Bucket Challenge and ALS Canada's partnership with Brain Canada and the Government of Canada!
The Arthur J. Hudson Translational Team Grant was first announced on May 3, 2014 at the ALS Canada Research Forum and the inaugural competition deadline was July 1, 2014. This new grant program is designed to fund teams of Canadian researchers to accelerate the movement of ideas out of the laboratory and into the clinic with the hope of assisting development of new therapeutics for ALS. It is the cornerstone of our ALS Canada Research Program designed to emphasize bench-to-bedside translation. For the first time ever, ALS Canada, in partnership with Brain Canada, have utilized an International Peer Review Panel consisting of seven European and American ALS experts, spanning the basic to clinical spectrum, who convened in Toronto in November to determine the top project amongst strong competition.
It is a great pleasure to announce that the recipient of the first Arthur J. Hudson Translational Team Grant is a team led by Dr. Lawrence Korngut, MD at the University of Calgary and also includes Dr. Lorne Zinman, MD from Sunnybrook Health Sciences Centre and University of Toronto. Together, they will pursue “A randomized controlled trial of pimozide in subjects with ALS”; a Phase II study involving 100 participants across 8 ALS clinics across Canada.
This trial, led by the Principal Investigator of the Canadian Neuromuscular Disease Registry (CNDR) and the Chair of the Canadian ALS Research Network (CALS) will examine whether pimozide, a drug already approved by Health Canada for use in psychoses like schizophrenia and Tourette’s syndrome, might slow progression of ALS. Pimozide is particularly effective at stabilizing neuromuscular function, which means it can strengthen the connection where the motor neuron meets the muscle (called the neuromuscular junction or NMJ). It is hoped that by strengthening this connection, there will be preservation of transmission of signals from the brain to the muscle and slowing of paralysis in ALS.